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Abstract 
Identification of subgroups of chemotherapy patients with distinct sleep disturbance profiles and 
associated co-occurring symptoms 
by Maria Tejada 
Problem: Sleep disturbance is a prevalent symptom that affects up to 88% of oncology patients. 
It is a significant problem for oncology patients due to its association with increased fatigue, 
depression and vasomotor/endocrine symptoms; poorer functional status and QOL; and 
potentially disease progression.  
Study Objectives: Study purposes were to identify subgroups of patients with distinct sleep 
disturbance profiles and to evaluate for differences in demographic, clinical, and various sleep 
characteristics, as well for differences in the severity of co-occurring symptoms among these 
subgroups.  
Methods: Outpatients with breast, gynecological, gastrointestinal, or lung cancer (n=1331) 
completed questionnaires six times over two chemotherapy (CTX) cycles. Sleep disturbance was 
evaluated using the General Sleep Disturbance Scale (GSDS). Latent profile analysis was used to 
identify distinct subgroups. 
Results: Three latent classes with distinct sleep disturbance profiles were identified (Low 
(25.5%), High (50.8%), Very High (24.0%)). Approximately 75% of the patients had a mean 
total GSDS score that was above the clinically meaningful cutoff score of t43 across all six 
assessments. Compared to patients in the Low class, patients in High and Very High classes were 
significantly younger; had a lower functional status; had higher levels of comorbidity; and were 
more likely to be female, more likely to have childcare responsibilities, less likely to be 
employed, and less likely to have gastrointestinal cancer. For all of the GSDS subscale and total 
 vi 
scores, significant differences among the latent classes followed the expected pattern 
(Low<High<Very High). For trait and state anxiety, depressive symptoms, morning and evening 
fatigue, decrements in attentional function, and decrements in morning and evening energy, 
significant differences among the latent classes followed the expected pattern (Low<High<Very 
High). 
Conclusions: Clinicians need to perform in-depth assessments of sleep disturbance and co-
occurring symptoms to identify high-risk patients and recommend appropriate interventions. 
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Introduction 
 
Sleep disturbance is a pervasive symptom that affects 30% to 88% of oncology patients.1-
4 Sleep disturbance is a significant problem for oncology patients due to its association with 
increased fatigue,5-7 depression,8 and vasomotor/endocrine symptoms;9 poorer functional 
status10,11 and quality of life (QOL);11 and potentially disease progression.11,12 
While chemotherapy (CTX) is a common and widely used cancer treatment, limited 
research is available on changes in sleep disturbance during this treatment. In a meta-synthesis of 
ten cross-sectional and nine longitudinal studies on sleep disturbance in women with breast 
cancer receiving CTX,13 findings on sleep disturbance were inconsistent. While some studies 
found worsening sleep disturbance over time, others did not find significant changes. These 
discrepancies may be the result of the various instruments used to evaluate sleep disturbance and 
inconsistencies in the timing of the assessments throughout the continuum of CTX. In addition, 
several of these studies had small sample sizes, included only patients with breast cancer, and 
evaluated sleep disturbance at a limited number of time points.  
In a more recent longitudinal study that was not included in the meta-synthesis cited 
above,14 sleep disturbance was assessed in breast cancer patients at three time points during CTX 
(i.e., before, after cycle 4, and at one-year post-CTX). Sleep disturbance was measured using 
actigraphy and the Pittsburg Sleep Quality Index (PSQI). When breast cancer patients were 
compared to healthy cancer-free women, the breast cancer patients had worse sleep quality at 
enrollment. Furthermore, in the women with breast cancer, while sleep disturbance worsened at 
cycle 4, it returned to baseline levels by one-year post-CTX. In another longitudinal study of 
breast cancer patients,15 sleep disturbance was assessed using the PSQI at three time points (i.e., 
3 to 14 days prior to starting CTX, day 1 of cycle 4, and 6 months after initiation of CTX). While 
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no significant changes were found over time, patients reported poor sleep quality at all three 
assessments. Both of these studies had small sample sizes (n=68, 14 n=80 15), included only 
breast cancer patients, and assessed sleep disturbance at a limited number of time points.  
In the studies cited above, various objective and subjective measures were used to 
evaluate sleep disturbance. The PSQI was the most commonly used subjective measure and 
actigraphy was the most commonly used objective measure. The sleep characteristics assessed in 
these studies included one or more of the following measures: objective sleep quality, subjective 
sleep quality, nocturnal sleep characteristics (i.e., nocturnal sleep time, sleep-onset latency, 
nocturnal awakenings), day sleep time, daytime sleepiness, and insomnia symptoms.13-15 It is 
important to note that not all of the aforementioned studies evaluated for all of these sleep 
disturbance characteristics.  
Given that oncology patients receiving CTX rarely experience a single symptom, 
emerging evidence suggests that an evaluation of the severity of common co-occurring 
symptoms is warranted.16-18 For example, in a previous study by our research team, using the 
Memorial Symptom Assessment Scale (MSAS), a total of 25 symptoms were reported by over 
40% of the patients receiving CTX.19 The five most common co-occurring symptoms out of the 
25 were: lack of energy, difficulty sleeping, pain, feeling drowsy, and difficulty concentrating. 
Of note, this study did not evaluate for the severity of these common co-occurring symptoms.  
While a number of studies have reported on the occurrence and deleterious impact of 
sleep disturbance in oncology patients,9,10,20 limited information is available on how sleep 
disturbance changes during CTX; the severity of various sleep disturbance characteristics, and 
the severity of the most common co-occurring symptoms. Therefore, the purposes of this study 
were: to identify subgroups of patients with distinct sleep disturbance profiles using latent profile 
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analysis (LPA) and to evaluate for differences in demographic, clinical, and various sleep 
characteristics, as well for differences in the severity of common co-occurring symptoms among 
these subgroups.  
Methods 
 
Patients and Settings 
This study is part of a longitudinal study, funded by the National Cancer Institute, that 
evaluated the symptom experience of oncology outpatients receiving CTX.21-23 Patients were 
eligible if they: were >18 years of age; had a diagnosis of breast, gastrointestinal (GI), 
gynecological (GYN), or lung cancer; had received CTX within the preceding four weeks; were 
scheduled to receive at least two additional cycles of CTX; were able to read, write, and 
understand English; and provided written informed consent. Patients were recruited from two 
Comprehensive Cancer Centers, a Veterans Affairs hospital, and four community-based 
oncology programs. A total of 2,234 patients were approached and 1,343 consented to participate 
(60.1% response rate). The major reason for refusal was being too overwhelmed with their 
cancer treatment. For this study, 1331 patients completed the General Sleep Disturbance Scale 
(GSDS). 
Instruments 
Demographic information was obtained using a questionnaire that included age, gender, 
ethnicity, marital status, living arrangements, education, employment status, child and elder care 
responsibilities, exercise regularity, and annual income. Patients’ self-reported their functional 
status using the Karnofsky Performance Status (KPS) scale that ranged from 30 (I feel severely 
disabled and need to be hospitalized) to 100 (I feel normal; I have no complaints or symptoms).24  
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The Self-Administered Comorbidity Questionnaire (SCQ) was used to assess 
comorbidity. The questionnaire consists of 13 common medical conditions that were simplified 
into language that could be understood without any prior medical knowledge.25 It allowed 
patients to note the severity of a comorbidity by indicating if they had the condition; if they 
received treatment for it; and if it limited their activities. For each condition, a patient can receive 
a maximum of 3 points and the total SCQ score ranges from 0 to 39. The SCQ has well-
established validity and reliability and has been used in studies of patients with a variety of 
chronic conditions.26 
 The GSDS consists of 21 items designed to assess the various aspects of sleep 
disturbance (i.e., quality, quantity, onset latency, mid and early awakenings, sleep medications, 
daytime sleepines). Each item was rated on a 0 (never) to 7 (everyday) numeric rating scale 
(NRS). The GSDS total score ranges from 0 (no disturbance) to 147 (extreme sleep disturbance). 
Each mean subscale score ranges from 0 to 7. Subscale scores of >3 and a GSDS total score of 
t43 indicate a significant level of sleep disturbance that warrants clinical evaluation and 
management.27 The GSDS has well-established validity and reliability.28-30 In this study, the 
Cronbach’s alpha for the GSDS total score was 0.83.  
The Spielberger State-Trait Anxiety Inventories (STAI-T and STAI-S) each have 20 
items that are rated from 1 to 4. The summed scores for each scale can range from 20 to 80. The  
STAI-S measures a person’s temporary anxiety response to a specific situation or how anxious or 
tense a person is “right now” in a specific situation. The STAI-T measures a person’s 
predisposition to anxiety as part of one’s personality. Cutoff scores of >31.8 and >32.2 indicate 
high levels of trait and state anxiety, respectively. The STAI-S and STAI-T inventories have well 
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established validity and reliability.31-33 In the current study, the Cronbach’s alphas for the STAI-
T and STAI-S were 0.92 and 0.96, respectively. 
The Attentional Function Index (AFI) consists of 16 items designed to measure 
attentional function.34 A higher total mean score on a 0 to 10 NRS indicates greater capacity to 
direct attention. Total scores are grouped into categories of attentional function (i.e., <5.0 low 
function, 5.0 to 7.5 moderate function, >7.5 high function).35 The AFI has well established 
reliability and validity.34 In this study, the Cronbach’s alpha for the total AFI scores was 0.93. 
The Center for Epidemiological Studies-Depression scale (CES-D) consists of 20 items 
selected to represent the major symptoms in the clinical syndrome of depression. A total score 
can range from 0 to 60, with scores of >16 indicating the need for individuals to seek clinical 
evaluation for major depression. The CES-D has well established validity and reliability.36-38 In 
the current study, the Cronbach’s alpha for the CES-D total score was 0.89. 
The Lee Fatigue Scale (LFS) consists of 18 items designed to assess physical fatigue and 
energy.39 Each item was rated on a 0 to 10 NRS. Total fatigue and energy scores were calculated 
as the mean of the 13 fatigue items and the 5 energy items, respectively. Higher scores indicate 
greater fatigue severity and higher levels of energy. Using separate LFS questionnaires, patients 
were asked to rate each item based on how they felt within 30 minutes of awakening (i.e., 
morning fatigue, morning energy) and prior to going to bed (i.e., evening fatigue, evening 
energy). The LFS has established cut-off scores for clinically meaningful levels of fatigue (i.e., 
≥3.2 for morning fatigue, ≥5.6 for evening fatigue)27 and energy (i.e., d6.2 for morning energy, 
d3.5 for evening energy). 27 It was chosen for this study because it is relatively short, easy to 
administer, and has well established validity and reliability.39-41 In the current study, the 
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Cronbach’s alphas were 0.96 for morning and 0.93 for evening fatigue and 0.95 for morning and 
0.93 for evening energy. 
Occurrence of pain was evaluated using the Brief Pain Inventory.42 Patients who 
responded yes to the question about having pain were asked to indicate if their pain was or was 
not related to their cancer treatment. Patients were categorized into one of four groups (i.e., no 
pain, only noncancer pain, only cancer pain, both cancer and noncancer pain).  
Study Procedures 
The study was approved by the Committee on Human Research at the University of 
California, San Francisco and the Institutional Review Board at each of the study sites. Patients 
were approached by a research staff member in the infusion unit to discuss participation in the 
study. Written informed consent was obtained from all patients. Given the challenges associated 
with the recruitment of patients prior to their first cycle of CTX, patients were recruited during 
their second or third cycle of CTX. Depending on the length of their CTX cycle, patients 
completed questionnaires in their homes, a total of six times over two cycles of CTX (i.e., prior 
to CTX administration (i.e., recovery from previous CTX cycle, assessments 1 and 4), 
approximately 1 week after CTX administration (i.e., acute symptoms, assessments 2 and 5), 
approximately 2 weeks after CTX administration (i.e., potential nadir, assessments 3 and 6)). 
Disease and treatment information were collected from medical records. 
Data Analysis 
 Descriptive statistics and frequency distributions were calculated for the demographic 
and clinical characteristics using Statistical Package for the Social Sciences (SPSS) version 23 
(International Business Machines, Armonk, NY). Differences among the latent classes were 
evaluated using analyses of variance (ANOVA) or Chi Square analyses. The Bonferroni 
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procedure was used to calculate the post hoc contrasts. A p-value of <.05 was considered 
statistically significant. 
Latent profile analysis (LPA) of sleep disturbance 
Unconditional LPA was used to identify the profiles of sleep disturbance means for the 
total score from the GSDS that characterized unobserved subgroups (i.e., latent classes) of 
patients over the six assessments. Typically, growth mixture modeling or latent class growth 
modeling of change trajectories would be used to identify latent classes of individuals who 
change differently over time. However, the data from this study demonstrated a complex pattern 
of change because a pre-treatment assessment, an immediate post-treatment assessment, and a 
second post-treatment assessment were done over two cycles of CTX (i.e., assessments 1, 2, and 
3 and assessments 4, 5, and 6). We expected that the trajectory of change for sleep disturbance, 
measured six times, over two treatment cycles would have a twin peak pattern that looks like 
“Λ_Λ”. Therefore, we identified latent classes of patients based on their profiles of means, where 
the means were estimated from the GSDS total scores measured on six occasions. In order to 
incorporate the expected correlations among the repeated measures, we included covariance 
among GSDS scores that were one or two occasions apart (i.e., a covariance structure with a lag 
of two). In this way, we retained the within-person correlation among the GSDS scores, at the 
same time that we focused on the patterns of means that distinguished the latent classes. We 
limited the covariance structure to a lag of two to accommodate the expected reduction in 
correlation that would be introduced by two treatments within each set of three measurement 
occasions, and to reduce model complexity. 
Estimation was carried out with full information maximum likelihood with standard 
errors and a Chi-square test that are robust to non-normality and non-independence of 
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observations (“estimator=MLR”). Model fit was evaluated to identify the best solution that 
characterized the observed latent class structure with the Bayesian Information Criterion (BIC), 
the Vuong-Lo-Mendell-Rubin likelihood ratio test (VLMR) for the K vs. K-1 model, entropy, 
and latent class percentages that were large enough to be reliable (i.e., likely to replicate in new 
samples; 15% or about 85 patients).43,44 Missing data were accommodated with the use of the 
Expectation-Maximization (EM) algorithm.45  
Mixture models, like LPA, are known to produce solutions at local maxima. Therefore, 
our models were fit with from 1,000 to 2,400 random starts. This approach ensured that the 
estimated model was replicated many times and was not due to a local maximum. Estimation 
was done with Mplus Version 7.2. 43 
Results 
Latent Classes for Sleep Disturbance 
Although the BIC for the four-class solution was lower than the three-class solution, the 
three-class solution was selected because one of the classes in the four-class solution was too 
small to be reliable and because the profile of means for two of the classes in the four-class 
solution did not differ in a meaningful way (i.e., either by profile or mean levels of GSDS total 
scores; Table 1). In addition, the three-class solution fit better than the two-class solution (lower 
BIC, VLMR test) and the profiles of means were clinically meaningfully different.  
As shown in Figure 1, the trajectories for sleep disturbance scores differed among the 
latent classes. Because a clinically meaningful total GSDS score for sleep disturbance is t43,27 
the sleep disturbance classes were named Low, High, and Very High. For both the Low (25.2%) 
and the Very High (24.0%) classes, sleep disturbance scores remained relatively constant across 
the six assessments. In contrast, for the High Sleep Disturbance class (50.8%), sleep disturbance 
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scores oscillated over the two cycles of CTX, with slightly higher scores reported at assessments 
2 and 5 (i.e., the weeks following the administration of CTX).  
Differences in Demographic and Clinical Characteristics Among the Sleep Disturbance Classes 
Compared to patients in the Low Sleep Disturbance class, patients in the High and Very 
High classes were significantly younger, had a lower KPS score, and a higher SCQ score (Table 
2). Furthermore, compared to the Low Sleep Disturbance class, patients in the High and Very 
High classes were more likely to be female, less likely to be currently employed, more likely to 
have childcare responsibilities, and less likely to have a GI cancer diagnosis. In addition, 
compared to the Low and High Sleep Disturbance classes, patients in the Very High class had a 
higher body mass index (BMI), were less likely to be married or partnered, were more likely to 
live alone, and reported a lower annual household income. The remainder of the demographic 
and clinical characteristics did not differ among the sleep disturbance classes.  
Differences in GSDS Subscale Scores Among the Sleep Disturbance Classes 
 
 As shown in Table 3, differences were found among the sleep disturbance classes for all 
of the GSDS subscale scores and total sleep disturbance score at enrollment (all p<.001). For all 
of the subscales of the GSDS (i.e., sleep quality, sleep quantity, sleep onset latency, mid-sleep 
awakenings, early awakenings, medications for sleep, and excessive daytime sleepiness scores 
[all p<.001]), as well as for the total GSDS score, these significant differences among the three 
latent classes followed the expected pattern (i.e., Low < High < Very High).  
Severity of Co-occurring Symptoms Among the Latent Classes  
 As shown in Table 4, differences were found among the sleep disturbance classes in the 
severity scores for all of the co-occurring symptoms at enrollment (all p<.001). Trait and state 
anxiety, depressive symptoms, and morning and evening fatigue scores followed the expected 
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pattern (i.e., Low < High < Very High). Attentional function, as well as morning and evening 
energy scores followed the opposite but expected pattern (i.e., Low > High > Very High). In 
terms of pain, the post hoc contrasts for no pain (i.e., Low > High > Very High) and for having 
both cancer and non-cancer pain (i.e., Low < High < Very High) were in the expected directions.  
Discussion 
 To our knowledge, this study is the first to use LPA to identify subgroups of patients with 
distinct sleep disturbance trajectories at six time points over two cycles of CTX. Approximately 
75% of the patients had a mean total GSDS score that was above the clinically meaningful cutoff 
score of t43 across all six assessments. Of note, this occurrence rate falls at the higher end of the 
range of sleep disturbance rates reported in studies of the general oncology population (i.e., 30% 
to 88%).1-4 The mean total GSDS score of our patients at enrollment (i.e., 52.5) is above the 
scores reported by patients at the initiation of radiation therapy (i.e., 44.3 (breast cancer), 34.5 
(prostate cancer)46) and prior to breast cancer surgery (i.e., 48.147). In addition, the total GSDS 
scores of our patients were comparable to the scores reported by mothers of a newborn infant 
(i.e., 55.548) and permanent nightshift workers (i.e., 60.529). While the global GSDS scores 
among our latent classes were significantly different (Table 3), patients in the Very High class 
reported higher levels of sleep disturbance (i.e., 74.4) when compared to another latent class 
analysis of women following breast cancer surgery (i.e., High Sustained class – GSDS score of 
58.049). Taken together, these findings suggest that a significant number of patients receiving 
CTX have very high levels of sleep disturbance for over 6 to 8 weeks.  
 As shown in Table 3, the GSDS subscale scores provide additional information about the 
types of sleep disturbance experienced by our three groups of patients. Across all three classes, 
patients reported insufficient quantity of sleep (i.e., t3 days of not getting enough sleep in the 
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past week). Patients in the High and Very High classes reported significantly poorer quality of 
sleep and higher scores for the two subscales associated with sleep maintenance (i.e., mid-sleep 
awakenings, early awakenings). In addition, patients in the Very High class reported higher 
scores for difficulty initiating sleep (i.e., sleep onset latency) and excessive daytime sleepiness 
(i.e., 3.8 days out of the week). Consistent with previous studies,46,47,49 for all three classes, the 
use of sleep medications was low. Based on these findings, oncology clinicians need to assess 
patients for sleep disturbance and use a multimodal approach that includes education about sleep 
hygiene and short-term use of medications to treat this symptom.  
In terms of demographic characteristics associated with higher levels of sleep 
disturbance, our findings are consistent with previous studies that found that younger oncology 
patients reported higher levels of sleep disturbance.49-51 In contrast, while some studies found no 
gender differences,52,53 others found that female patients reported more sleep disturbance.54-57 
The higher prevalence of sleep disturbance in women may be explained by the concept of a 
“double work day”, where in addition to working a full-time job, women in traditional family 
roles work a “second-shift” completing household tasks and caring for children.29 Another 
potential explanation is the influence of hormonal changes on sleep-wake activity.58  
While limited data are available to support an association between being 
married/partnered and worse sleep disturbance, our finding suggests that having a partner who 
can provide support and assistance during CTX may alleviate some of the stressors that could 
contribute to sleep disturbance. Similarly, limited research exists to support our finding that 
unemployment and having a lower household income is associated with worse sleep disturbance. 
One possible explanation for this finding may be that poorer living conditions and financial 
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stress associated with these sociodemographic factors can independently predispose an 
individual to experience sleep disturbance.  
 In terms of clinical characteristics that differentiated among the latent classes, our 
findings are consistent with previous studies of patients with heterogenous cancer diagnoses. For 
example, poorer functional status10,28,47,49,59-62 and worse comorbidity profiles47,49 were 
associated with higher levels of sleep disturbance. Consistent with a previous study of patients 
who underwent breast cancer surgery,47 patients with a higher BMI had worse levels of sleep 
disturbance. While we did not evaluate for obstructive sleep apnea (OSA), this condition is 
common in patients with a higher BMI. In particular, excessive daytime sleepiness, a cardinal 
feature of OSA interferes with nocturnal sleep.63-65  
Furthermore, a relationship exists between a higher BMI and lack of regular exercise,66 
which was associated with higher levels of sleep disturbance in our patients. In terms of clinical 
implications, the positive impact of exercise on sleep is well studied. In a systematic review of 
56 randomized control trials and quasi-randomized controlled trials of cancer patients receiving 
active treatment,67 the effects of exercise on QOL outcomes were evaluated. Compared to 
patients in the non-exercise or usual care groups, patients in the intervention groups had 
significant reductions in sleep disturbance as well as other QOL outcomes (i.e., anxiety, 
depression, fatigue, physical functioning, emotional well-being, role function). With regards to a 
specific cancer diagnosis, limited research is available on the association between GI cancer and 
the levels of sleep disturbance found in our patients. However, to our knowledge, this study is 
the first to identify differences in sleep disturbance severity in patients across four different 
cancer diagnoses. 
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In terms of the differences in the severity of common co-occurring symptoms among the 
latent classes, patients who reported higher levels of sleep disturbance also experienced higher 
levels of physical fatigue, depression, and anxiety and lower levels of energy and decrements in 
attentional function. Consistent with a previous study of sleep disturbance in women undergoing 
breast cancer surgery,49 patients in the Very High class reported symptom severity scores well 
above the cutoff scores for clinically meaningful levels for all of the co-occurring symptoms 
mentioned above. Furthermore, confirmed in our study and in previous reports of breast cancer 
patients,5,68-71 a positive correlation exists between sleep disturbance and fatigue before CTX. 
Consistent with another study of breast cancer patients,72 women who reported higher sleep 
disturbance experienced decrements in attentional function prior to the initiation of radiation 
therapy. 
In terms of the association between higher sleep disturbance and increased depressive 
symptoms, our findings are consistent with previous reports of breast cancer patients before,73 
during,60,71,74 and after74,75 adjuvant CTX. Similarly, in one study,76 a relationship was found 
between disturbed sleep and increased anxiety in women prior to breast cancer surgery. In 
addition, while limited data are available on the association between the occurrence of pain and 
sleep disturbance, the occurrence rate for pain of 72.6% in our overall sample is higher than the 
rate of 59% reported in a systematic review.77 While we did not evaluate for specific pain 
conditions, based on the conditions listed on the SCQ, compared to patients in the Low and High 
classes, patients in the Very High class reported higher rates of back pain. Of note, with the 
exception of the systematic review of pain,77 the studies cited above included only breast cancer 
patients. Additional studies are needed to evaluate the impact of co-occurring symptoms on sleep 
disturbance in patients receiving CTX.  
14 
 
Limitations 
 Several limitations need to be acknowledged. Because patients were not recruited prior to 
the initiation of CTX, changes in sleep disturbance prior to the initiation of treatment were not 
assessed. Patients in this sample were predominantly White, female, college educated, and had 
metastatic disease, which suggests that our study sample may not be entirely representative of 
oncology patients in the United States. While the sample size was very large, which increases the 
generalizability of the study findings, these patients received a variety of CTX regimens. As a 
result, differences in sleep disturbance associated with different CTX regimens cannot be 
evaluated. Lastly, our study included only subjective measures of sleep disturbance. Future 
studies should include both subjective and objective measures of sleep disturbance. 
Conclusions 
 Despite these limitations, this study is the first to use LPA to identify subgroups of 
patients with distinct sleep disturbance profiles over two cycles of CTX. In addition, this study is 
the first to evaluate for differences in the severity of co-occurring symptoms among the sleep 
disturbance latent classes. This study identified some potentially modifiable demographic (e.g., 
employment status) and clinical characteristics (e.g., BMI, exercise) associated with a worse 
sleep disturbance trajectory. Based on these findings, clinicians who care for oncology patients 
receiving CTX need to perform an in-depth assessment of sleep disturbance and common co-
occurring symptoms to identify high-risk patients. In addition, it is important that clinicians 
educate these patients about sleep hygiene principles and determine whether short term use of 
sleep medications is needed.  
 Future longitudinal studies should enroll patients prior to the initiation of CTX and 
follow them to the completion of CTX. This approach will help confirm the specific latent 
15 
 
classes identified in this study and determine if the severity of sleep disturbance persists 
throughout the patient’s course of CTX. Additional research is needed to evaluate for 
interactions between common co-occurring symptoms and whether their impact on sleep 
disturbance trajectories is associated with higher levels of sleep disturbance. Finally, more 
studies are warranted to evaluate the efficacy of specific interventions to improve sleep 
throughout the continuum of CTX.  
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Figure 1. Changes in Sleep Disturbance trajectories for the three latent classes over six 
time points 
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Table 1 – General Sleep Disturbance Latent Profile Solutions and Fit Indices for One- Through 
Four-Class Solutions  
 
Model             LL      AIC  BIC             Entropy VLMR 
     
 
1 Class  -28080.06 56208.12 56332.77                   n/a n/a 
 
2 Class  -27692.33 55458.66 55650.83 .70 775.46**** 
 
3 Classa -27447.03 54994.05 55253.74 .73 490.61**** 
 
4 Class  -27323.81  54773.63 55100.83 .68 46.43* 
 
na Baseline LL, not applicable for one class; * p < .05; **** p < .0001 
 
a The three class solution was selected because the BIC for this solution was lower than the BIC 
for the 2-class solution. In addition, although the BIC was lower for the 4-class solution, two 
classes in the 4-class solution were not clinically different and had similar profiles. Therefore, 
the 3-class solution was selected because it fit better than the 2-class solution, identified three 
clinically different profiles, and was more parsimonious than the 4-class solution. In addition, the 
VLMR was significant for the 3-class solution, indicating that three classes fit the data better 
than two classes, and entropy was larger for the 3-class compared to the 4-class solution. 
 
Abbreviations: AIC = Akaike’s Information Criterion; BIC = Bayesian Information Criterion; LL = 
log-likelihood; VLMR = Vuong-Lo-Mendell-Rubin likelihood ratio test for the K vs. K-1 model. 
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